Literature DB >> 15927356

Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4.

A E Pedersen1, S Buus, M H Claesson.   

Abstract

We investigated the anti CT26 tumour effect of dendritic cell based vaccination with the MuLV gp70 envelope protein-derived peptides AH1 and p320-333. Vaccination lead to generation of AH1 specific cytotoxic lymphocytes (CTL) and some decrease in tumour growth of simultaneously inoculated CT26 cells. After combination with an antibody against VEGF receptor 2 (DC101), a significant increase in survival of the tumour cell recipients was observed. Also, monotherapy with an antibody against CTLA-4 (9H10), led to approximately 100% survival of tumour cell recipients. However, effective treatment of mice with already established tumours was only obtained after combination of vaccination, DC101 and 9H10 treatment in which setting 80% of the mice rejected their tumours.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15927356     DOI： 10.1016/j.canlet.2005.04.012

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  17 in total

1.  Anti-angiogenesis immunotherapy.

Authors:  Jonathan D Schoenfeld; Glenn Dranoff
Journal:  Hum Vaccin       Date:  2011-09-01

Review 2.  Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.

Authors:  Dmitriy Zamarin; Amir A Jazaeri
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

Review 3.  Immunotherapy in human colorectal cancer: Challenges and prospective.

Authors:  Xuan Sun; Jian Suo; Jun Yan
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

4.  Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.

Authors:  Taha Merghoub; Maria Jure-Kunkel; Jedd D Wolchok; Margaret K Callahan; Gregg Masters; Christine A Pratilas; Charlotte Ariyan; Jessica Katz; Shigehisa Kitano; Valerie Russell; Ruth Ann Gordon; Shachi Vyas; Jianda Yuan; Ashok Gupta; Jon M Wigginton; Neal Rosen
Journal:  Cancer Immunol Res       Date:  2014-01       Impact factor: 11.151

5.  89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging.

Authors:  Edmund J Keliher; Jeongsoo Yoo; Matthias Nahrendorf; Jason S Lewis; Brett Marinelli; Andita Newton; Mikael J Pittet; Ralph Weissleder
Journal:  Bioconjug Chem       Date:  2011-11-07       Impact factor: 4.774

Review 6.  New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.

Authors:  Siwen Hu-Lieskovan; Antoni Ribas
Journal:  Cancer J       Date:  2017 Jan/Feb       Impact factor: 3.360

Review 7.  Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.

Authors:  Chrisann Kyi; Michael A Postow
Journal:  Immunotherapy       Date:  2016-06       Impact factor: 4.196

Review 8.  CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

Authors:  Joseph F Grosso; Maria N Jure-Kunkel
Journal:  Cancer Immun       Date:  2013-01-22

9.  An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.

Authors:  Khairunadwa Jemon; Vivienne Young; Michelle Wilson; Sara McKee; Vernon Ward; Margaret Baird; Sarah Young; Merilyn Hibma
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

10.  The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies.

Authors:  Benjamin A H Jensen; Sara R Pedersen; Jan P Christensen; Allan R Thomsen
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.